Cosentyx is a biologic drug used to treat immune disorders such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a monoclonal antibody that works by blocking the action of a protein called interleukin-17A (IL-17A). This protein is involved in the inflammation process, which is a key factor in the development of these disorders. Cosentyx is administered as an injection under the skin or as an intravenous infusion. Cosentyx is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It is the first and only IL-17A inhibitor approved for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is also the first biologic drug approved for the treatment of ankylosing spondylitis. Cosentyx is marketed by Novartis, a Swiss multinational pharmaceutical company. Other companies in the market include AbbVie, Amgen, and Janssen Biotech. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
